News & Updates
Filter by Specialty:
Expectant mums’ use of dolutegravir safe for babies
Treatment with dolutegravir during pregnancy does not appear to pose an excess risk of adverse birth outcomes, according to two studies presented at the 24th International AIDS Conference in Montreal, Canada.
Expectant mums’ use of dolutegravir safe for babies
07 Aug 2024
![[PD Test]HCV cure possible in people who inject drugs despite poor treatment adherence](https://sitmspst.blob.core.windows.net/images/articles/hepatitis-cshutterstock411039529-cdb585d1-179f-4b5e-b24e-ae4fea616e0b-square.jpg)
[PD Test]HCV cure possible in people who inject drugs despite poor treatment adherence
People who inject drugs (PWID) with low adherence to sofosbuvir/velpatasvir can still be cured of hepatitis C virus (HCV) infection, suggests a study.
[PD Test]HCV cure possible in people who inject drugs despite poor treatment adherence
07 Aug 2024
Long-acting injectable HIV drug works for all ages
The long-acting combination of cabotegravir plus rilpivirine, administered as monthly or once-every-2-months jabs, appears to be effective in both older and younger patients living with HIV, with most maintaining virologic suppression through week 96, according to pooled data from the phase III ATLAS, FLAIR, and ATLAS-2M studies.
Long-acting injectable HIV drug works for all ages
06 Aug 2024
Novel agent plus ritonavir show favourable signals for mild-to-moderate COVID-19
A combination regimen comprising the novel agent GST-HG171 (also known as atilotrelvir) and ritonavir improves clinical symptom recovery and viral clearance in low-risk vaccinated adults with mild-to-moderate COVID-19, findings from a pivotal phase II/III study have shown.
